Tekmira Pharmaceuticals Corporation Provides Update on Collaboration With U.S. Government's TMT Program

VANCOUVER, British Columbia, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today disclosed that the temporary stop-work order announced on August 6, 2012 with respect to Tekmira's TKM-Ebola program has now been lifted by the U.S. Department of Defense (DoD) and work will continue on advancing TKM-Ebola under the existing contract.

Back to news